HBM Healthcare Investments has sold a majority stake in Swixx Biopharma to SK Capital Partners for over €1.5 billion, marking a significant milestone aimed at accelerating global expansion in pharmaceutical commercialization.

Information on the Target

Swixx Biopharma, a specialized distributor of medicinal products focusing on rare diseases, prescription medications, and over-the-counter drugs, has been a prominent player in the pharmaceutical sector. Based in the rapidly growing markets of Central and Eastern Europe, as well as Eurasia and the Middle East, Swixx has successfully established itself as a leading provider of commercialization services for global biopharma clients. The company, which has demonstrated significant revenue growth from EUR 40 million in 2017 to an anticipated EUR 1.3 billion by 2026, currently operates in 45 countries worldwide.

Through its comprehensive platform, Swixx offers expertise in the commercialization of rare disease treatments, oncology, hematology, and specialty therapies. This unique positioning within the pharmaceutical landscape has attracted the attention of several investors who recognize the potential for expansion and innovation in addressing the needs of underserved patient populations.

Industry Overview in the Target’s Specific Country

The pharmaceutical industry in Switzerland is characterized by its high degree of innovation and research, driven by leading firms in biotechnology and pharmaceutical development. As a hub for global health-related enterprises, Sw